Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 2/20 | 0.39 |
| ▸ | MC5R | P33032 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235398 | 0.86 | CARM1 (0.47) | HTTCYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL21066534 | 0.86 | SMN1; SMN2 (0.46) | CYP1A2CYP2D6CYP2C19CYP3A4CARM1 | |
| SCHEMBL14293669 | 0.83 | HDAC3 (0.47) | HTTCARM1PRMT6HDAC3HDAC1 | |
| SCHEMBL2854317 | 0.79 | SMN1; SMN2 (0.46) | HTTCYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL4413484 | 0.79 | CHRM2 (0.62) | HTTCYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL3456835 | 0.78 | HRH3 (0.44) | HTTHDAC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13966247 | 0.75 | CARM1 (0.40) | CYP1A2CYP2D6CYP2C19CYP3A4CARM1 | |
| SCHEMBL4790413 | 0.75 | CHRM2 (0.53) | HTTCYP1A2CYP2D6CYP2C19CYP3A4 | |
| SCHEMBL13206205 | 0.75 | LMNA (0.44) | HTTCARM1PRMT6KDM1AHDAC3 | |
| SCHEMBL5940081 | 0.74 | HDAC3 (0.47) | HTTHDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608352-B1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2009-12-30 | — | — | EP | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7504422-B2 | Polyamine compounds | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2009-03-17 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-7399776-B2 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2008-07-15 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-03-06 | — | — | US | disclosed |
| WO-2008021788-A2 | POLYAMINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (CN) | 2008-02-21 | — | — | WO | disclosed |
| EP-1608352-A4 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2007-11-28 | — | — | EP | disclosed |
| EP-1608352-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | Taigen Biotechnology (TW) | 2005-12-28 | — | — | EP | disclosed |
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | TAIGEN BIOTECHNOLOGY (TW) | 2005-02-24 | — | — | US | disclosed |
| WO-2004089360-A1 | POLYAMINE COMPOUNDS FOR TREATING CHEMOKINE RECEPTOR MEDIATED DISEASES | TAIGEN BIOTECHNOLOGY (TW) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043366-A1 | Polyamine compounds for treating chemokine receptor mediated diseases | CCL2, CCR2, CCR5 | HTT 2956/4885CYP1A2 4408/4885CYP2D6 4807/4885 |
| US-20080058382-A1 | POLYAMINE COMPOUNDS | SRM, SMS, SMOX | HTT 2763/4885CYP1A2 4355/4885CYP2D6 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.